Litcius/Paper detail

Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

Ngoc H. Tan, Daryl Geers, Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Susanne Bogers, Laura L.A. van Dijk, Lennert Gommers, Leanne P. M. van Leeuwen, Annemarie Boerma, Sander Nijhof, Karel A. van Dort, Marion Koopmans, Virgil A. S. H. Dalm, Melvin Lafeber, Neeltje A. Kootstra, Anke Huckriede, Debbie van Baarle, Luca M. Zaeck, Corine H. GeurtsvanKessel, Rory D. de Vries, P.H.M. van der Kuy

2023The Lancet Infectious Diseases36 citationsDOIOpen Access PDF

Topics & Concepts

Bivalent (engine)VaccinationMedicineImmunogenicityBooster (rocketry)VirologyImmunologyAntigenChemistryPhysicsOrganic chemistryMetalAstronomySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial | Litcius